Announcements Trials
Browse Landscape

Phase

Phase 2 48Phase 1 25Phase 1/2 22Phase 3 11Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Azacitidine × 90 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07581002 2026-05-12

REVIVAL

AbbVie

Phase 2/3 Not yet recruiting
660 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
216 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡